The vision of Life Science Leader is to be an essential business tool for life science executives. Our content is designed to not only inform readers of best practices, but motivate them to implement those best practices in their own businesses.
Issue link: https://lifescienceleadermag.epubxp.com/i/118943
Pharma Management whereby they will work together to explore diabetes treatment and care. A similar move was made by Geisinger Health System and Merck, which recently embarked on a multi-year collaboration designed to improve patient health outcomes by focusing on solutions that facilitate shared decision making between patients and physicians and improve adherence to treatment plans and clinical care processes. Teams from Geisinger and Merck will work together to improve patient adherence, increase the role of patients in making decisions to help manage their conditions, share information among extended care teams, and improve clinical care processes. The first tool being developed is an interactive web application designed to help primary care clinicians assess and engage patients at risk for cardiometabolic syndrome — the risk factors that put an individual at risk of developing Type 2 diabetes and cardiovascular disease. "It has been slow, but that equation is changing considerably with payors and providers opening to collaboration, but the process is being initiated by the pharmaceutical companies, and smart industry executives understand which payors and providers are willing to engage in this different model," says Edmunds. "When we see the partnership work, it's because both sides are jointly developing solutions rather than a pharma company developing a solution and trying to push it or the payor/provider asking for something and shopping around to see what pharma company can satisfy its request. This collaborative model takes investment and the mindset from both sides to build successfully." Successfully fulfilling the resolution to get in shape this year will leave many LSLs struggling with the realization that they have to change how they operate and not be afraid to risk moving too far away from current business models. In the big world of clinical trials, it's the small stuff that counts. &ƌŽŵůĂƌŐĞƉŚĂƌŵĂƚŽŶŝĐŚĞďŝŽƚĞĐŚ ǁĞƵŶĚĞƌƐƚĂŶĚĂŶĚŵĞĞƚLJŽƵƌƵŶŝƋƵĞƌĞƋƵŝƌĞŵĞŶƚƐ͘ >ĞƚWZƚĂŝůŽƌĮƚĂŶŝŶŶŽǀĂƟǀĞƐƚƌĂƚĞŐLJƐƉĞĐŝĮĐĂůůLJĨŽƌLJŽƵ͘ clearlypra.com >ĞĂƌŶŵŽƌĞ ĂďŽƵƚŽƵƌ ƚĂŝůŽƌĞĚ ƐŽůƵƟŽŶƐ WŚĂƐĞ/ /s &Ƶůů ^ĞƌǀŝĐĞŝŽƉŚĂƌŵĂĐĞƵƟĐĂůƌƵŐĞǀĞůŽƉŵĞŶƚ dƌĂŶƐĨŽƌŵŝŶŐůŝŶŝĐĂůdƌŝĂůƐƚŚƌŽƵŐŚ KƵƌWĞŽƉůĞ /ŶŶŽǀĂƟŽŶ - Transparency ΞWZϮϬϭϯ ůůZŝŐŚƚƐZĞƐĞƌǀĞĚ ϯ ϭϯ